OnKure Therapeutics (OKUR) Q3 2025 earnings summary

Executive summary

• First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination therapies for metastatic breast cancer.

• Clinical data from single agent and combination arms of PIKture-01 expected in Q1 2026, alongside initial triplet arm data.

• Significant progress in next-generation PI3Ka pan-mutant inhibitor program, with multiple candidates identified and announcement planned for Q1 2026.

• Expansion into vascular malformations program, with further details to be provided in 2026.

Financial highlights

• Cash and cash equivalents were $70.3 million as of September 30, 2025, expected to fund operations into Q4 2026.

• R&D expenses rose to $11.9 million in Q3 2025 from $10.1 million in Q3 2024, mainly due to increased personnel and share-based compensation.

• G&A expenses increased to $3.6 million in Q3 2025 from $1.4 million in Q3 2024, driven by higher personnel, director compensation, and professional fees.

• Net loss for Q3 2025 was $14.7 million ($1.09 per share), compared to $11.6 million ($36.55 per share) in Q3 2024.

Outlook and guidance

• Initial data from PIKture-01 monotherapy, fulvestrant combination, and triplet expansion arms expected in Q1 2026.

• Next-generation PI3Ka pan-mutant inhibitor candidate announcement planned for Q1 2026.

• Additional information on vascular malformations program to be announced in 2026.